Skip to main
We’re doing some system maintenance
  1. /
  2. Stocks
  3. /
  4. I-Mab
IMAB

Buy I-Mab (IMAB) Stock

IMAB
See IMAB stock price and Buy/Sell I-Mab with any amount of money. Discuss news and analysts' price predictions with the investor community.
Sign up to start investing
IMAB

I-Mab (IMAB)

About I-Mab (IMAB)

I-Mab operates as a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel or differentiated biologics to treat diseases with unmet medical needs, particularly cancers and autoimmune disorders. The company was founded by Jingwu Zang on June 30, 2016 and is headquartered in Pudong, China.
Market Cap
$378.1M
1 Year High
$76.81
Volume
6
1 Year Low
$4.47
Price to Earnings Ratio
Open
$4.47
Dividend Rate
High
$4.68
Dividend Yield
Low
$4.47

Community

People who own or watch IMAB stock

I-Mab Price Targets

What analysts think IMAB stock price will be.
$4.55
$34.47
657.6% Upside
$4$81

I-Mab Stock Rating

What analysts recommend for IMAB stock, on a scale from 1(buy) to 5(sell).
Strong Buy1 / 5
BuyHoldSell

I-Mab Stock Earnings

The value each IMAB share was expected to gain vs. the value that each IMAB share actually gained.
Expected
Actual

I-Mab Stock News

Frequently Asked Questions (FAQ)

As of Sep 26, 2022, the market cap for I-Mab stock is $378.1M

The 52-week high for I-Mab stock is $76.81. The current I-Mab stock price $4.55 is 94.08% below its 52-week high

The 52-week low for I-Mab stock is $4.47. The current I-Mab stock price $4.55 has increased 1.76% from its 52-week low

No, the I-Mab stock does not pay dividends to its shareholders

The target price for I-Mab stock is $34.47 based on the average of what a group of analyst think I-Mab stock could be worth at a future date. This is not a prediction by Public.com

Buy I-Mab (IMAB) Stock

IMAB
See IMAB stock price and Buy/Sell I-Mab with any amount of money. Discuss news and analysts' price predictions with the investor community.
Sign up to start investing

Community

People who own or watch IMAB stock
  • katelinl avatar
  • ceejaay avatar
  • billp avatar
  • opyekongozob avatar
  • jdk123 avatar
Check the background of this firm on FINRA’s BrokerCheck.

© Copyright 2022 Public Holdings, Inc. All Rights Reserved.

Market data powered by Xignite.

Securities are offered to self-directed customers by Open to the Public Investing, Inc. (“Open to the Public Investing”), a registered broker-dealer and member of FINRA & SIPC. Additional information about your broker can be found by clicking here. Open to Public Investing is a wholly-owned subsidiary of Public Holdings Inc. (“Public Holdings”). This is not an offer, solicitation of an offer or advice to buy or sell securities, or open a brokerage account in any jurisdiction where Open to the Public Investing is not registered. Securities products offered by Open to the Public Investing are not FDIC insured.

Cryptocurrency execution and custody services are provided by Apex Crypto LLC (NMLS ID 1828849) through a software licensing agreement between Apex Crypto LLC and Public Crypto LLC. Apex Crypto is not a registered broker-dealer or a member of SIPC or FINRA. Cryptocurrencies are not securities and are not FDIC or SIPC insured. Apex Crypto is licensed to engage in virtual currency business activity by the New York State Department of Financial Services. Please ensure that you fully understand the risks involved before trading: Legal Disclosures

Commission-free trading of stocks and ETFs refers to $0 commissions for Open to the Public Investing self-directed individual cash brokerage accounts that trade the U.S. listed securities electronically. Keep in mind, that other fees such as regulatory fees, Premium subscription fees, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Open to the Public Investing’s Fee Schedule to learn more.

All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns.